
News|Articles|August 1, 2002
Voriconazole: A novel azole antifungal agent (PDF)
In late May, voriconazole (Vfend) received approval for the treatment of invasive aspergillosis and as salvage therapy for treatment of Scedosporium apiospermum and Fusarium infections. In addition to these infections, voriconazole has excellent invitro activity against both Candida and Aspergillus species, including good activity against fluconazole- and itraconazole-resistant species. This Focus article reviews the antifungal's pharmacology, pharmacokinetics, efficacy in clinical trials, safety, dosing, price, and place in therapy.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Daraxonrasib trial exceeds expectations after decades of disappointment in pancreatic cancer drug development
2
340B reform and drug shortages are among hospital pharmacy concerns, survey finds
3
Dual-target ADC shows promising PFS signal in mCRPC | ASCO 2025
4
Alyana Samai, M.P.H. | 2026 MHE Emerging Leaders in Healthcare
5


























